About DRAXIMAGE

History

As the Frosst Radiopharmaceutical Division, DRAXIMAGE pioneered and became a leader in the medical application of nuclear technology after assuming the development function from Atomic Energy of Canada Ltd. in the early fifties. DRAXIMAGE has a long history of technological and scientific progress.

DRAXIMAGE was one of the first companies to develop lyophilized kits for the in-situ preparation of Technetium-99m radiopharmaceuticals. The company was also a leader in identifying the critical role that peptides would play in the revitalization of Nuclear Medicine and successfully developed chelates for both the Indium/Yttrium and Technetium/Rhenium group of metals. 

1955    

Radiopharmaceutical Development and Manufacturing commences at Charles E. Frosst. The division was founded and led by Dr. Ralph Jamieson - a pioneer in Canadian Radiopharmaceuticals.
1965 Merck Inc., (Rahway N.J). purchases Charles E. Frosst and the company becomes Merck Frosst Radiopharmaceuticals. 
1969

The company moves to a new custom-built facility in Kirkland, Quebec.
1973 Frosst Radiopharmaceuticals introduces its first Technetium-99m Generator.
1975 First lyophilized kits developed for Technetium-99m.
1980 Merck Frosst Radiopharmaceuticals starts export of lyophilized kits to the US.
1987 New formulation high capacity stabilized lyophilized kits introduced
1997 DRAXIS Health Inc. purchases Merck Frosst Radiopharmaceuticals and forms a new subsidiary DRAXIMAGE Inc.
1998 DRAXIS Health Inc. purchases the former Glaxo Welcome building in Kirkland as the new home for DRAXIMAGE.
1998 DRAXIMAGE starts construction of a fully automated lyophilization line and new hot labs in the DRAXIS Health building.
1999 DRAXIMAGE moves operations from Merck Frosst to the DRAXIS Health building.
2001 DRAXIMAGE doubles manufacturing capacity for radiopharmaceuticals and medical devices.
2003 DRAXIMAGE introduces Kit for the preparation of I-131 therapeutic capsules and solution in the USA.  DRAXIMAGE receives ISO-9001 certification.
2004 DRAXIMAGE presents data from FIBRIMAGE® and INFECTON® at the SNM Annual Meeting.
2005 DRAXIMAGE Inc. and DRAXIS Pharma Inc. are amalgamated to form DRAXIS Specialty Pharmaceuticals Inc., and DRAXIMAGE continues operating as a division.
DRAXIMAGE receives first European approval for DRAXIMAGE® MAA Kit.

 

Our Original Home - Charles E. Frosst

 

An early Minitec Generator

An early Minitec Generator
Early Frosst Minitec Generator with a chrome plated lead shield

 

Ralph Jamieson and Raymond Dore
Ralph Jamieson & Raymond Doré